Cover Image
市場調查報告書

化療誘發性貧血:開發中產品分析

Chemotherapy Induced Anemia - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 192523
出版日期 內容資訊 英文 50 Pages
訂單完成後即時交付
價格
Back to Top
化療誘發性貧血:開發中產品分析 Chemotherapy Induced Anemia - Pipeline Review, H2 2017
出版日期: 2017年08月29日 內容資訊: 英文 50 Pages
簡介

化療誘發性貧血是治療癌症時最常見的副作用。有嚴重疲勞、虛勞、焦慮症、缺乏體力,呼吸急促,頭痛,血色壞,心搏過速,心跳,胸部疼痛,暈眩,認知功能障礙,性慾衰退,無法執行日常活動,伴隨貧血的憂鬱症等症狀。原因有年齡,併發症、經常性治療等。

本報告提供化療誘發性貧血的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

化療誘發性貧血概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

化療誘發性貧血:企業開發中的治療藥

化療誘發性貧血:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

化療誘發性貧血:企業開發中的產品

化療誘發性貧血的治療藥的開發企業

  • 3SBio Inc.
  • BIOCAD
  • Chong Kun Dang Pharmaceutical Corp.
  • Dr. Reddy's Laboratories Limited
  • Galenica Ltd.
  • Panacea Biotec Limited
  • Pfizer Inc.
  • PharmaEssentia Corporation
  • PhytoHealth Corporation
  • Pieris Pharmaceuticals Inc
  • Sandoz International GmbH
  • SBI Pharmaceuticals Co., Ltd.
  • Therapure Biopharma Inc.
  • Tolero Pharmaceuticals, Inc.

化療誘發性貧血:治療藥的評估

  • 單劑產品
  • 並用治療藥
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

化療誘發性貧血:暫停中的計劃

化療誘發性貧血:開發中止的產品

化療誘發性貧血:產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9670IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Anemia - Pipeline Review, H2 2017, provides an overview of the Chemotherapy Induced Anemia (Toxicology) pipeline landscape.

Chemotherapy-induced anemia is a very common side effect of cancer treatment. Symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain dizziness, cognitive impairment, loss of sexual desire, inability to perform daily functions and/or depression associated with anemia. The predisposing factors include age, co-morbidities, time course of therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Anemia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Anemia (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chemotherapy Induced Anemia (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Anemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 1, 2 and 4 respectively.

Chemotherapy Induced Anemia (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Anemia (Toxicology).
  • The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Anemia (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chemotherapy Induced Anemia (Toxicology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chemotherapy Induced Anemia (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Anemia (Toxicology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Anemia (Toxicology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Anemia (Toxicology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Chemotherapy Induced Anemia - Overview
    • Chemotherapy Induced Anemia - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Chemotherapy Induced Anemia - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Chemotherapy Induced Anemia - Companies Involved in Therapeutics Development
    • 3SBio Inc
    • Chong Kun Dang Pharmaceutical Corp
    • Galenica Ltd
    • Novartis AG
    • Panacea Biotec Ltd
    • Pfizer Inc
    • PharmaEssentia Corp
    • PhytoHealth Corp
    • SBI Pharmaceuticals Co Ltd
    • Therapure Biopharma Inc
    • Tolero Pharmaceuticals Inc
  • Chemotherapy Induced Anemia - Drug Profiles
    • (aminolevulinic acid hydrochloride + sodium ferrous citrate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • darbepoetin alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • darbepoetin alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • epoetin alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • epoetin zeta biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ferric carboxymaltose - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegylated erythropoietin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PHEP-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SSS-06 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TBI-304H - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TP-0184 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Chemotherapy Induced Anemia - Dormant Projects
  • Chemotherapy Induced Anemia - Discontinued Products
  • Chemotherapy Induced Anemia - Product Development Milestones
    • Featured News & Press Releases
      • Mar 11, 2015: Therapure Innovations Receives FDA Approval to Proceed with a Phase 1 Clinical Trial of Its Novel Anemia Therapeutic TBI 304H
      • Oct 30, 2012: SBI Pharmaceuticals Submits a Phase-1 Clinical Trial CTA to MHRA for a Drug to Treat Cancer Chemotherapy-induced Anemia
      • Apr 24, 2012: SBI Pharmaceuticals Announces Obtainment of Marketing Authorization of Products Containing 5-ALA from The Kingdom of Bahrain Ministry of Health
      • Oct 28, 2011: ALA Study Results Presented at the 49th Annual Meeting of Japan Society of Clinical Oncology
      • Oct 21, 2011: ALA Study Results Presented at 39th Annual Meeting of Japanese Association for Acute Medicine
      • Oct 05, 2011: ALA Study Results Presented at Japanese Cancer Association, 70th Annual Meeting
      • Oct 03, 2011: ALA Study Results Presented at Japanese Society of Parasitology, 71st Meeting
      • Mar 18, 2011: Announcement of publication of ALA research in International Immunopharmacology
      • Sep 30, 2010: Safety study for subcutaneous epoetin alfa biosimilar Binocrit/Epoetin alfa Hexal/Abseamed suspended
      • Dec 01, 2008: International presentation of clinical safety and efficacy data for Binocrit, the world's first complex biosimilar
      • Jan 07, 2008: Sandoz and Gambro form strategic alliance
      • Aug 31, 2007: European Commission approves Sandoz's epoetin alfa Binocrit
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Chemotherapy Induced Anemia, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Chemotherapy Induced Anemia - Pipeline by 3SBio Inc, H2 2017
  • Chemotherapy Induced Anemia - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017
  • Chemotherapy Induced Anemia - Pipeline by Galenica Ltd, H2 2017
  • Chemotherapy Induced Anemia - Pipeline by Novartis AG, H2 2017
  • Chemotherapy Induced Anemia - Pipeline by Panacea Biotec Ltd, H2 2017
  • Chemotherapy Induced Anemia - Pipeline by Pfizer Inc, H2 2017
  • Chemotherapy Induced Anemia - Pipeline by PharmaEssentia Corp, H2 2017
  • Chemotherapy Induced Anemia - Pipeline by PhytoHealth Corp, H2 2017
  • Chemotherapy Induced Anemia - Pipeline by SBI Pharmaceuticals Co Ltd, H2 2017
  • Chemotherapy Induced Anemia - Pipeline by Therapure Biopharma Inc, H2 2017
  • Chemotherapy Induced Anemia - Pipeline by Tolero Pharmaceuticals Inc, H2 2017
  • Chemotherapy Induced Anemia - Dormant Projects, H2 2017
  • Chemotherapy Induced Anemia - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Chemotherapy Induced Anemia, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top